Clopidogrel for the secondary prevention of stroke

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Patients experiencing transient ischemic attack (TIA) or ischemic stroke (IS) face a significant risk of recurrence.
• Platelet function inhibition effectively reduces secondary vascular events in TIA and stroke patients.
• Established antiplatelet agents include acetylsalicylic acid (ASA), clopidogrel, ticlopidine, and ASA plus slow-release dipyridamole.

Purpose of the Study:

• To analyze recent trial results and discuss ongoing/future trials involving clopidogrel and its combination with ASA.
• To evaluate the efficacy of clopidogrel versus ASA in preventing vascular events.
• To identify high-risk patient subgroups who benefit most from clopidogrel and to present a predictive model for treatment selection.

Main Methods:

• Review and analysis of recent clinical trials on antiplatelet therapy for secondary vascular event prevention.
• Examination of data from trials involving clopidogrel monotherapy and combination therapy with ASA.
• Presentation of a prediction model for identifying patients who benefit from clopidogrel over ASA.

Main Results:

• Clopidogrel demonstrates superior efficacy to ASA in preventing vascular events in patients with IS, myocardial infarction (MI), or peripheral arterial disease (PAD).
• The benefit of clopidogrel over ASA is most pronounced in high-risk populations, including diabetics, post-coronary bypass surgery patients, and those with a history of ischemic events.
• Combination therapy with clopidogrel and ASA is more effective than ASA alone for patients with coronary stent implantation, unstable angina, or non-Q-wave MI.
• In high-risk TIA/stroke patients, adding ASA to clopidogrel did not improve outcomes compared to ASA monotherapy but increased bleeding complications.

Conclusions:

• Clopidogrel is a superior option to ASA for secondary vascular event prevention in specific patient groups, particularly those at high risk.
• Combination therapy of clopidogrel and ASA offers benefits in certain acute coronary syndromes and post-procedural settings.
• Further large-scale trials are investigating long-term combination therapy, emphasizing the need for careful risk-benefit assessment due to increased bleeding risks.